期刊
TRENDS IN PHARMACOLOGICAL SCIENCES
卷 30, 期 3, 页码 148-155出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2008.12.002
关键词
-
资金
- National Institutes of Health
- Michael J. Fox Foundation
- Seaside Therapeutics
- Vanderbilt University
- NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH073676, R01MH082867, U54MH084659] Funding Source: NIH RePORTER
Muscarinic acetylcholine receptors (mAChRs) have long been viewed as viable targets for novel therapeutic agents for the treatment of Alzheimer's disease (AD) and other disorders involving impaired cognitive function. More recent evidence indicates that mAChR activators might also have utility in treating psychosis and other symptoms associated with schizophrenia and other central nervous system (CNS) disorders. Efforts to develop mAChR subtype-selective agonists have been hampered by difficulty in achieving high selectivity for individual mAChR subtypes important for CNS function (M-1 and M-4) and adverse effects due to activation of peripheral mAChRs (especially M-2 and M-3). Major advances have now been achieved in the discovery of allosteric agonists and positive allosteric modulators of M-1 and M-4 that show greater selectivity for individual mAChR subtypes than do previous mAChR agonists. Early studies indicate that these allosteric mAChR activators have properties needed for optimization as potential clinical candidates and have robust effects in animal models that predict efficacy in the treatment of AD, schizophrenia and related disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据